The twice-yearly injectable, which significantly reduces HIV incidence compared with oral regimens, has high adherence and manageable adverse effects.
Jessica Lai, PharmD
Advertisement
Lai, PharmD, is an infectious diseases pharmacy resident at the University of Maryland Medical Center in Baltimore.
Articles by Jessica Lai, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
COVID-19: The Gaps in Science Communication
2
Unlocking New Defenses: The Changing Landscape of Candida auris Management
3
Top Infectious Disease News Stories Week of January 3 - January 9
4
Prospective Game Changer: Lenacapavir for HIV Preexposure Prophylaxis
5